白细胞介素-6作为头颈部肿瘤根治性放化疗患者影像学乏氧动态的替代标志物:一项前瞻性先导试验结果
这项前瞻性先导试验纳入27例接受根治性放化疗的头颈部鳞状细胞癌患者,连续采集血样检测血浆白细胞介素-6(IL-6),并在治疗第0、2、5周以[18F]FMISO PET/CT评估肿瘤内乏氧。IL-6与治疗期间肿瘤内乏氧亚体积强相关,第2周IL-6可预测早期乏氧反应,第5周IL-6升高与总生存下降相关。作者认为血浆IL-6是肿瘤乏氧动态的有前景替代标志物。
要点
- 基线、第2周、第5周平均IL-6浓度分别为15.1、19.6、31.0 pg/mL。
- IL-6与治疗期间肿瘤内乏氧亚体积强相关(基线r=0.775,第2周r=0.553,第5周r=0.734)。
- 第2周IL-6预测早期乏氧反应AUC=0.822(p=0.031),第5周IL-6升高与总生存下降相关(p=0.013)。
核心结论
- 作者认为血浆IL-6是头颈部鳞状细胞癌患者肿瘤乏氧动态的有前景替代标志物,可能有助于乏氧导向的个体化放疗概念。
研究设计与样本
- 前瞻性先导试验纳入27例接受根治性放化疗的头颈部鳞状细胞癌患者,连续采集血样分析血浆IL-6。
- 在治疗第0、2、5周使用[18F]FMISO PET/CT评估肿瘤内乏氧。
- 采用Pearson相关和多元回归分析PET乏氧与IL-6的关联,并用受试者工作特征分析确定IL-6预测肿瘤乏氧反应的诊断效能。
- 该前瞻性试验在德国临床试验注册中心注册(DRKS00003830),注册日期为2015年8月20日。
主要发现
- 基线、第2周、第5周平均IL-6浓度分别为15.1、19.6、31.0 pg/mL。
- 吸烟(p=0.050)和体能状态下降(p=0.011)导致IL-6水平更高,而肿瘤分期(p=0.427)、淋巴结分期(p=0.334)、肿瘤部位(p=0.439)和HPV状态(p=0.294)无影响。
- IL-6水平与治疗期间肿瘤内乏氧亚体积强相关:基线r=0.775(p<0.001),第2周r=0.553(p=0.007),第5周r=0.734(p<0.001)。
- 无早期肿瘤乏氧反应患者的第2周IL-6水平更高(p=0.016),第2周IL-6预测早期乏氧反应AUC=0.822(p=0.031)。
- 第5周IL-6水平升高导致无进展生存期呈下降趋势(p=0.078),总生存期下降(p=0.013)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intratumoral hypoxia increases resistance of head-and-neck squamous cell carcinoma (HNSCC) to radiotherapy. [18F]FMISO PET imaging enables noninvasive hypoxia monitoring, though requiring complex logistical efforts. We investigated the role of plasma interleukin-6 (IL-6) as potential surrogate parameter for intratumoral hypoxia in HNSCC using [18F]FMISO PET/CT as reference. METHODS: Within a prospective trial, serial blood samples of 27 HNSCC patients undergoing definitive chemoradiation were collected to analyze plasma IL-6 levels. Intratumoral hypoxia was assessed in treatment weeks 0, 2, and 5 using [18F]FMISO PET/CT imaging. The association between PET-based hypoxia and IL-6 was examined using Pearson's correlation and multiple regression analyses, and the diagnostic power of IL-6 for tumor hypoxia response prediction was determined with receiver-operating characteristic analyses. RESULTS: Mean IL-6 concentrations were 15.1, 19.6, and 31.0 pg/mL at baseline, week 2 and week 5, respectively. Smoking (p=0.050) and reduced performance status (p=0.011) resulted in higher IL-6 levels, whereas tumor (p=0.427) and nodal stages (p=0.334), tumor localization (p=0.439), and HPV status (p=0.294) had no influence. IL-6 levels strongly correlated with the intratumoral hypoxic subvolume during treatment (baseline: r=0.775, p<0.001; week 2: r=0.553, p=0.007; week 5: r=0.734, p<0.001). IL-6 levels in week 2 were higher in patients with absent early tumor hypoxia response (p=0.016) and predicted early hypoxia response (AUC=0.822, p=0.031). Increased IL-6 levels at week 5 resulted in a trend towards reduced progression-free survival (p=0.078) and overall survival (p=0.013). CONCLUSION: Plasma IL-6 is a promising surrogate marker for tumor hypoxia dynamics in HNSCC patients and may facilitate hypoxia-directed personalized radiotherapy concepts. TRIAL REGISTRATION: The prospective trial was registered in the German Clinical Trial Register (DRKS00003830). Registered 20 August 2015.
引用
- Rühle A, Wiedenmann N, Fennell JT, et al. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial. Eur J Nucl Med Mol Imaging. 2021. PMID: 34773163. doi:10.1007/s00259-021-05602-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。